In an exclusive with "The Gray Sheet," Ken Stein, Boston Scientific's chief medical officer for cardiac rythm management, says CMS's denial of new-technology add-on payment for their Watchman device is actually good news. He also spoke about expanding the indication for the left-atrial appendage closure device and possibly getting a national coverage determination by the end of the year.
